Royce & Associates’s Quest Diagnostics DGX Stock Holding History

Royce & Associates’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-117,000	Closed	-$8.99M	–	1221
2015 Q1	$8.99M	Sell	117,000 -159,800	-58%	-$11.4M	0.03%	616
2014 Q4	$18.6M	Buy	276,800 +63,800	+30%	+$4.03M	0.06%	377
2014 Q3	$12.9M	Buy	213,000 +25,500	+14%	+$1.57M	0.04%	509
2014 Q2	$11M	Sell	187,500 -1,100	-0.6%	-$64.4K	0.03%	634
2014 Q1	$10.9M	Buy	188,600 +17,500	+10%	+$938K	0.03%	637
2013 Q4	$9.16M	Buy	171,100 +15,250	+10%	+$904K	0.03%	695
2013 Q3	$9.63M	Buy	155,850 +34,850	+29%	+$2.09M	0.03%	676
2013 Q2	$7.34M	Buy	+121,000	New	+$7.21M	0.02%	742

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Royce & Associates's DGX Position: Q2 2015 in Review

Royce & Associates sold out of Quest Diagnostics (DGX) in Q2 2015, closing a stake of 117,000 shares — an estimated $8.99M sold.

Royce & Associates first reported a position in DGX in Q2 2013 and held it in 8 quarters. The position peaked at $18.6M in Q4 2014. 542 funds tracked by Wall St. Rank hold DGX as of Q2 2015.

Royce & Associates reported no remaining Quest Diagnostics position as of Q2 2015 after selling out during the quarter.
Royce & Associates sold 117,000 Quest Diagnostics shares in Q2 2015, an estimated $8.99M.
Royce & Associates first reported a position in Quest Diagnostics in Q2 2013 and held it in 8 quarters.
Royce & Associates's Quest Diagnostics position peaked at $18.6M in Q4 2014.
542 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2015.

Based on Royce & Associates's 13F filing for Q2 2015, filed 10 Aug 2015.